BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) is a chemokine involved in monocyte recruitment during inflammation whose plasma level is elevated in obesity. OBJECTIVE: The present studies were designed to examine the release of MCP-1 in primary culture by explants of visceral adipose tissue from morbidly obese women. RESULTS: Most of the MCP-1 released by adipose tissue explants was derived from the nonfat cells in adipose tissue. The release of MCP-1 by adipose tissue explants was upregulated almost five-fold between 3 and 48 h of incubation. Approximately half of this upregulation was due to the release of endogenous tumor necrosis factor a (TNFa) and IL-1b based on the ability of a combination of a soluble TNFa receptor (etanercept) and a blocking antibody against IL-1b to reduce MCP-1 release. The release of MCP-1 over 48 h was unaffected by insulin or dexamethasone but significantly reduced by the combination of both agents. MCP-1 release was reduced by 60% in the presence of an inhibitor of the nuclear factor kB (NF-kB) pathway. There were no significant effects of inhibitors of p44/42 mitogen-activated protein kinase (ERK), Jun N-terminal kinase (JNK) and p38 mitogenactivated protein kinase (p38 MAPK) pathways on MCP-1 release. However, inhibition of MCP-1 release in the presence of inhibitors of both the p38 MAPK and NF-kB pathways was greater than that seen with only the NF-kB inhibitor. DISCUSSION: The present data shows that MCP-1 formation is upregulated over a 48-h incubation of primary explants of visceral adipose tissue. Half of this upregulation is dependent upon endogenous TNFa and Il-1b and involves the p38 MAPK and NF-kB pathways.
Introduction
Monocyte chemoattractant protein-1 (MCP-1) is a member of a family of chemotactic proteins (chemokines) that are involved in the recruitment of monocytes to sites of inflammation. 1 Elevated circulating levels of MCP-1 as well as MCP-1 mRNA have been reported in obese mice. 2, 3 Miller et al 4 found that depressed humans had an elevated body mass index (BMI) as compared to control subjects, which was accompanied by elevation in circulating IL-6 and C-reactive protein but not of MCP-1. Similar results were seen in obese children and adolescents where plasma IL-6 was positively correlated with the BMI, while there was no significant correlation between circulating MCP-1 and BMI. 5 Piemonti et al 6 reported that the plasma MCP-1 was elevated in Type 2 diabetic women and was associated with an increase in cardiovascular disease over a 7-y follow-up period. Rosiglitazone, a drug used to treat Type 2 diabetes, has been shown over a 6-week period to reduce plasma MCP-1. 7 Recently, 8, 9 it was reported that the plasma MCP-1 level as well as the MCP-1 mRNA content of subcutaneous adipose tissue is elevated in human obesity and that MCP-1 formation is greater in visceral than in subcutaneous adipose tissue of humans. Furthermore, MCP-1 mRNA was primarily found in the nonfat cells obtained by collagenase digestion of human adipose tissue rather than adipocytes and the addition of IL-1b or tumor necrosis factor a (TNFa) to isolated tissue explants incubated for 48 h in fresh medium after a prior overnight incubation-enhanced MCP-1 formation. 9 Mazurek et al 10 reported that the level of MCP-1 mRNA as well as secretion by human epicardial adipose tissue explants was greater than that seen in subcutaneous adipose tissue surrounding leg veins in patients undergoing elective coronary artery bypass surgery. Similar increases were seen in expression of other inflammatory markers such as IL-6, IL1b and TNFa in epicardial adipose tissue and attributed to the greater content of inflammatory cells such as macrophages, mast cells and T cells in epicardial as contrasted to subcutaneous fat. 10 The regulation of MCP-1 release has primarily been examined using preadipocytes differentiated into adipocytelike cells over 14 days of culture in the presence of insulin and dexamethasone. The level of MCP-1 and cyclophilin mRNA based on semiquantitative RT-PCR analysis remained constant over 14 days of culture, while that of IL-8, TNFa and macrophage inflammatory protein-1a decreased over the same time period. 11 It has been reported that TNFa enhances the expression of MCP-1 mRNA in differentiated human 11 as well as murine adipocytes. 12 In differentiated murine adipocytes, insulin enhances MCP-1 mRNA accumulation as well as MCP-1 release to the medium. 2 Furthermore, insulin administration to ob/ob mice elevated plasma levels of MCP-1, but no effect of insulin on plasma MCP-1 was seen in wild-type mice. 2 Insulin has also been reported to enhance MCP-1 formation in rat vascular smooth muscle cells. 13 However, insulin has been reported to lower elevated MCP-1 levels in obese humans 14 and Type 2 diabetics. 15 Aljada et al 16 found that insulin inhibited nuclear factor kB (NF-kB) activity and MCP-1 expression in human aortic endothelial cells. The present studies were designed to examine the signaling cascades that are involved in MCP-1 release. PGE 2 release was also examined as a comparison marker since it is involved in the inflammatory response and is released as a result of cyclooxygenase 2 (COX-2) upregulation during in vitro incubation of human subcutaneous adipose tissue explants. 17, 18 The release of PGE 2 by human adipose tissue is primarily due to the nonfat cells that accounted for 93% of total release over a 48-h incubation by the fractions obtained after collagenase digestion of human adipose tissue. 17, 18 We wanted to see if the release of MCP-1 is also by the nonfat cells. Furthermore, it has been reported that COX products serve as endogenous repressors of MCP-1 formation in experimental glomerulonephritis. 19 
Materials and methods
Visceral adipose tissue was obtained from obese women undergoing laparoscopic adjustable gastric banding surgery or laparoscopic gastric bypass with Roux-en-y gastroenterostomy surgery for the treatment of morbid obesity. The average BMI of the fat donors for each set of experiments is shown in the legends for the figures and The study had the approval of the local IRB and all patients involved gave their informed consent. The patients were on a 1000 kcal liquid diet for 2 weeks prior to surgery to facilitate laparoscopic surgery. Samples of visceral adipose tissue were immediately transported to the laboratory. The handling of tissue and cells was carried out under aseptic conditions. The tissue was cut with scissors into small pieces (5-10 mg). All the studies utilized explants of adipose tissue that had been incubated in buffer plus albumin (3 ml/g of tissue) for approximately 5-30 min to reduce contamination of the tissue with blood cells and soluble factors. At the conclusion of this incubation, the tissue explants were centrifuged for 30 s at 400 g in order to remove blood cells and make pieces of tissue containing insufficient adipocytes float. In some experiments, the cut pieces of tissue that did not float (connective tissue) were incubated to determine their release of IL-6 and other factors and are referred to as connective tissue. The connective tissue fragments and tissue explants were separated from the medium plus the sedimented cells and resuspended in fresh buffer. The explants (100 mg/ml) were then incubated in duplicate for the indicated times in suspension culture under aseptic conditions. Adipocytes were prepared by incubating 0.5 g of cut adipose tissue per ml of incubation medium containing 0.6 mg/ml of bacterial collagenase in a rotary water bath shaker (100 r.p.m.) for 2 h. The collagenase digest was then separated from undigested tissue matrix by filtration through 200 mm mesh fabric. About 5 ml of medium was then added back to the digestion tubes and used to wash the undigested matrix on the filter mesh. This wash solution was combined with the collagenase digest and SV cells were separated from adipocytes and medium by centrifugation in 15 ml tubes for 1 min at 400 g. The SV cells are defined as those cells isolated by collagenase digestion that do not float. The SV cells and adipocytes were each suspended in 5 ml of fresh buffer and centrifuged for 10 s at 400 g. The medium was removed and the undigested tissue matrix on the nylon mesh, the SV cells and the adipocytes were then incubated in a volume of 5 ml for the indicated periods.
The serum-free buffer for incubation of adipose tissue and adipocytes was as previously described. 17 The pH of the buffer was adjusted to 7.4 and then filtered through a 0.2 mm filter. Aliquots of the medium were stored at À201C for measurement of adipokine release to the medium. MCP-1 and transforming growth factor-b1 (TGF-b1) were determined by ELISA using Duoset reagents from R&D Systems of Minneapolis (MN, USA). PGE 2 was determined by radioimmunoassay as previously described. 
imidazole) inhibits p38 MAPK with an IC 50 of 60 nM and 50-1000-fold selectivity vs other protein kinases.
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Results MCP-1 release was examined after 2, 24 or 48-h incubation in primary culture using cut pieces of visceral adipose tissue. The studies shown in Figure 1a demonstrate that MCP-1 release was upregulated in adipose tissue over 48 h of incubation.
We also digested the cut pieces of adipose tissue with collagenase and then separated the stromalvascular (SV) cells from the adipocytes and the collagenase-resistant tissue matrix. The release of MCP-1 by these three fractions was compared to that by tissue explants over 48 h (Figure1b). Most of the MCP-1 release by adipose tissue was due to the nonfat cells (matrix þ SV cells) since release of MCP-1 by adipocytes was 9% of that by the three fractions obtained after collagenase digestion of adipose tissue. The release of MCP-1 by adipocytes was 4% of that by explants of adipose tissue over 48 h.
The earliest time period at which release by adipocytes can be compared to that by tissue explants is over 3-5 h of incubation because of the time required to isolate adipocytes from human tissue. In the experiments shown in Figure 1c , we compared release by tissue over 1-3 or 3-5 h and by adipocytes over 3-5, 5-7 and 7-9 h of incubation. The release by adipocytes per gram wet weight was also less than 5% of that by tissue over a 3-5 h incubation.
Since most of the MCP-1 release by adipose tissue was due to the nonfat cells, we examined MCP-1 release by the pieces of adipose tissue that do not contain enough lipid to float (connective tissue). These pieces of adipose tissue released as Regulation of MCP-1 release JN Fain and AK Madan much MCP-1 per gram wet weight as the pieces of cut tissue that contained enough lipid to float (Figure 2a ). Does the release of MCP-1 by explants of adipose tissue over 4 h requires some stimulus that is activated during removal of the adipose tissue from the humans and the cutting of the tissue into small pieces? The data in Figure 2b show that extensive cutting of the tissue is not required since the release to the medium of MCP-1 by one piece of adipose tissue was not significantly reduced as compared to that by minced tissue. Similar results were seen with respect to PGE 2 release.
The possibility that endogenous TNFa or IL-1b release by adipose tissue explants might be involved in the upregulation of MCP-1 over a 48-h incubation was examined by incubating explants in the presence of (1) etanercept, a recombinant protein that binds and inactivates human TNFa, (2) a monoclonal antihuman IL-1b antibody that binds and inactivates IL-1b, (3) or both. The combination of both agents at a concentration of 200 ng/ml but not at 50 ng/ ml markedly depressed MCP-1 formation over 48 h (Figure3). However, neither blocking agent alone significantly decreased MCP-1 release over 48 h. This was quite different from what was seen with respect to PGE 2 release that was inhibited by either blocking agent and the effect of both together appeared to be additive ( Figure 3) . We also examined the ability of the combination of etanercept (200 ng/ml) and the anti IL-1b antibody (200 ng/ml) to block MCP-1 release over a 4-h incubation by explants of human visceral adipose tissue. In six experiments, MCP-1 release was inhibited by 31711% as the mean7s.e.m., which was significant (PZ0.05).
The upregulation of cytokine release by human macrophages is dependent upon the NF-kB pathway and influenced by the p38 MAPK, ERK and JNK pathways. [24] [25] [26] In the studies shown in Table 1 , we examined the effect of the ERK, JNK II, p38 MAPK and NF-kB alone or in combination with each of the other inhibitors. The NF-kB inhibitor alone markedly inhibited both MCP-1 and PGE 2 formation; In the presence of the ERK inhibitor plus either the JNK or the p38 MAPK inhibitor, a reproducible inhibition of MCP-1 formation and almost total inhibition of PGE 2 formation was seen in visceral explants. The combination of 1 mM of the p38 MAPK inhibitor and 1 mM of the NF-kB inhibitor abolished MCP-1 release. However, combining the NF-kB inhibitor with the JNK inhibitor had no greater effect than the NF-kB inhibitor alone. There were differences between the effects of the drugs on PGE 2 as contrasted to MCP-1 formation (Table 1 ). In the presence of both the ERK and JNK inhibitors, PGE 2 formation was inhibited by 87% as contrasted to only a 33% inhibition of MCP-1 formation. Another difference was the near-maximal inhibition of PGE 2 formation by the p38 MAPK inhibitor that had only a small and insignificant effect on MCP-1 formation.
The data in Figure 4 show that in explants incubated for 48 h there was also a greater inhibition of PGE 2 release (95%) than of MCP-1 release (74%) by the combination of the inhibitors of the ERK, JNK, p38 MAPK and NF-kB pathways. The inhibitors had no effect on the release of TGF-b1 over a 48-h incubation indicating that the inhibition of MCP-1 and PGE 2 release is not due to nonspecific toxicity (Figure 4) .
Neither dexamethasone nor insulin alone had any effect on MCP-1 release by human visceral adipose tissue explants incubated for 48 h ( Figure 5 ). In contrast, 10 nM dexamethasone inhibited PGE 2 release over 48 h by 84%. The combination of insulin and dexamethasone inhibited MCP-1 release by 28%, but had no further effect on the marked reduction by dexamethasone alone of PGE 2 release.
Discussion
The present results indicate that there is appreciable release of MCP-1 by human visceral adipose tissue explants in primary culture. Previously, we examined the release of PGE 2 , IL-8, IL-6, plasminogen activator inhibitor (PAI-1), hepatocyte growth factor (HGF), IL-10, TNFa, vascular endothelial growth factor (VEGF) A and IL-1b by explants of visceral adipose tissue from women with similar BMI values. 17, 18 The release over 48 h of MCP-1 reported here was 17 Our results are similar to the finding that MCP-1 mRNA is primarily in the SV cells rather than the adipocytes isolated by collagenase digestion of human subcutaneous adipose tissue. 8, 9 The question of which cells in adipose tissue, other than adipocytes, produce and release MCP-1 remains to be answered. There was a greater release of MCP-1 to the medium by pieces of adipose tissue that did not contain enough lipid to float as compared to those pieces that did float. This indicates that on a wet weight basis the formation of MCP-1 is far greater by the nonfat-containing cells in human adipose tissue than by adipocytes. Most of the MCP-1 formation by the three fractions obtained after collagenase digestion of the tissue was in the tissue matrix, which is operationally defined as collagenase-digested adipose tissue that will not pass through a 200 mm mesh filter. The formation of MCP-1 by the undigested tissue matrix cells was over five-fold greater than that by the SV cells isolated from the same amount of adipose tissue. This is similar to what we found with respect to PGE 2 , IL-8, IL-6, PAI-1, HGF, IL-10, VEGF A and IL-1b formation. 17 However, TNFa formation was primarily by the SV cell fraction. 17, 27 The SV cells are those cells that pass through the filter, but do not float, and are separated from the adipocytes by brief centrifugation. The SV cell fraction includes blood cells, macrophages, preadipocytes and any other nonfat cells present in adipose tissue that are released by collagenase digestion. The SV cell fraction accounted for less than 16% of MCP-1 formation over 48 h. The possibility that MCP-1 formation in human adipose tissue is due to macrophage infiltration must be considered since obesity in rodents is associated with various degrees of macrophage accumulation in adipose tissue. 28, 29 Bruun et al Our data suggest that these cells and possibly the endothelial cells of adipose tissue capillaries, rather than adipocytes, account for most of the MCP-1 release by human adipose tissue as suggested by others. 8, 9 One prominent difference between the regulation of MCP-1 and other cytokines released by adipose tissue explants is the lack of an inhibitory effect of dexamethasone on MCP-1 release over a 48-h incubation. In contrast, we saw a marked inhibition of PGE 2 accumulation in the same experiments. These results indicate that in explants of visceral adipose tissue there is little effect of cyclooxygenase metabolites on MCP-1 formation differentiating the regulation of MCP-1 from that of other inflammatory cytokines such as IL-1b, IL-6 and IL-8. Previously we reported that dexamethasone markedly inhibited the release of haptoglobin, IL-8, IL-1b, VEGFA, IL-6 and IL-10, while having no effect on the release of adiponectin and stimulating the release of leptin over a 48-h incubation of explants of subcutaneous adipose tissue from massively obese humans. 31 The lack of a dexamethasone inhibition on MCP-1 formation by human visceral adipose tissue is in contrast to inhibitory effects Regulation of MCP-1 release JN Fain and AK Madan of dexamethasone on MCP-1 formation by human monocytes, 32 human articular cartilage 33 and human dermal fibroblasts. 34 Our demonstration that insulin alone has little effect on MCP-1 release by human adipose tissue explants suggests that the ability of insulin administration to obese 14 or diabetic humans 15 to lower circulating MCP-1 is not secondary to direct effects on adipose tissue. However, our ability to see an inhibition of MCP-1 release by insulin in the presence of dexamethasone suggests that the effects of insulin are complex and dependent upon the existing hormonal milieu. This is especially so since under some conditions insulin actually enhances MCP-1 formation. 2, 12, 13 It is hardly surprising that blocking the action of endogenous IL-1b and TNFa release by cut explants of adipose tissue reduced the upregulation of MCP-1. These cytokines induce similar genes in human umbilical vein endothelial cells where Zhao et al 35 found that it was necessary to suppress both cytokines simultaneously in order to ameliorate the inflammatory response. Similarly, we found that inhibition of the up-regulation of MCP-1 in human visceral adipose tissue explants over 48 h was markedly reduced (À58%) in the presence of antagonists of both IL-1b and TNFa. However, neither antagonist alone had a significant effect on MCP-1 formation. A similar inhibition of IL-8 and IL-6 release by visceral adipose tissue explants was seen in the presence of both Il-1b and TNFa antagonists. 36 In contrast, we found that either antagonist blocked PGE 2 release and their effect on PGE 2 release together was additive. The TNFa antagonist we used was etanercept that is a recombinant protein with a high affinity-binding site for TNFa, which is used clinically in the treatment of rheumatoid arthritis. 37 We used a monoclonal blocking antibody against human IL-1b for the in vitro studies, which should have effects similar to those of a human IL-1b receptor antagonist that is also effective in the treatment of rheumatoid arthritis. 38 Park et al 39 have shown that, in cultured pleural mesothelial cells, the induction of IL-8 formation by conditioned media from Mycobacterium tuberculosis-infected pleural macrophages was almost completely blocked by the combination of a soluble IL-1b receptor antagonist and an antibody against TNFa. In our experiments, using antagonists of both IL-1b and TNFa, MCP-1 formation was reduced by 50%. Hypoxia has been reported to upregulate MCP-1 expression in human dermal fibroblasts, 40 neonatal rat brain 41 and melanona cells. 42 The There was a significant inhibition of MCP-1 release in the presence of only the inhibitor of the NF-kB pathway but not with the inhibitor of JNK pathway, which actually reduces the effect of blocking the NFkB pathway. While neither the ERK nor the p38MAPK kinase inhibitors significantly reduced MAP-1 release they reduced MCP-1 release by 53% when combined. We conclude that in human adipose tissue the most important kinase pathway in the regulation of MCP-1 release is the NF-kB pathway and that the ERK and p38MAPK pathways can contribute to MCP-1 upregulation. The p38 MAPK kinase pathway, 49 the JNK pathway 50 and the NF-kB pathway 51 have all been implicated in the upregulation of COX-2 by IL-1b and TNFa. Most of the drugs that inhibit these kinases were products of the search for potent antiinflammatory agents that block the upregulation of COX-2 and thus block PGE 2 formation. We compared the effects of the inhibitors of the p38 MAPK, JNK kinase, ERK and NF-kB pathways on PGE 2 and found that when all were blocked there was little formation of PGE 2 . However, there were differences in the effects of drugs singly and in combination with each other, in that the p38 MAPK inhibitor markedly reduced PGE 2 formation while having little effect on MCP-1. This suggests that in human adipose tissue as in human monocytes 24 the p38 MAPK pathway is required for stabilization of the COX-2 mRNA. In monocytes there is a rapid disappearance of COX-2 mRNA when this pathway is blocked and this occurs even in the presence of actinomycin D. Furthermore, the greatest inhibition of PGE 2 formation was seen with the ERK inhibitor in combination with the p38 MAPK inhibitor, while this combination had a much less effect on MCP-1 formation. Inhibition of only the NF-kB pathway reduced MCP-1 formation by 60%, while blocking the ERK, JNK and p38 MAPK pathways had a much smaller effect. The NF-kB pathway is central in the control of inflammation because more than 60 proinflammatory genes
Regulation of MCP-1 release JN Fain and AK Madan have been shown to be regulated by NF-kB. 52 There are differences in the regulation of some of these genes since NFkB can bind to the IL-8 promoter through both p50/p65 and p65/p65 complexes, but to the MCP-1 promoter only through p50/p65 heterodimers. 53 Our data suggest that the NF-kB pathway is relatively more important in the regulation of MCP-1, while the p38 MAPK pathway is the most important for the regulation of PGE 2 formation.
In conclusion, the present results demonstrate that the release of MCP-1 is upregulated over a 48-h incubation of adipose tissue explants and approximately half of the release of MCP-1 can be blocked by the concomitant presence of inhibitors of endogenous TNFa and IL-1b. Even over a 4-h incubation of adipose tissue explants, most of the release of MCP-1 appears to be the result of upregulation since it can be blocked by an inhibitor of NF-kB activation. However, maximal upregulation appears to require the presence of both the NF-kB and the p38 MAPK pathways.
